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Shotgun metagenomic analysis of the human associated microbiome provides a rich set of
microbial features for prediction and biomarker discovery in the context of human diseases
and health conditions. However, the use of such high-resolution microbial features presents
new challenges, and validated computational tools for learning tasks are lacking. Moreover,
classification rules have scarcely been validated in independent studies, posing questions
about the generality and generalization of disease-predictive models across cohorts. In this
paper, we comprehensively assess approaches to metagenomics-based prediction tasks
and for quantitative assessment of the strength of potential microbiome-phenotype associations. We develop a computational framework for prediction tasks using quantitative microbiome profiles, including species-level relative abundances and presence of strain-specific
markers. A comprehensive meta-analysis, with particular emphasis on generalization
across cohorts, was performed in a collection of 2424 publicly available metagenomic samples from eight large-scale studies. Cross-validation revealed good disease-prediction
capabilities, which were in general improved by feature selection and use of strain-specific
markers instead of species-level taxonomic abundance. In cross-study analysis, models
transferred between studies were in some cases less accurate than models tested by
within-study cross-validation. Interestingly, the addition of healthy (control) samples from
other studies to training sets improved disease prediction capabilities. Some microbial species (most notably Streptococcus anginosus) seem to characterize general dysbiotic states
of the microbiome rather than connections with a specific disease. Our results in modelling
features of the “healthy” microbiome can be considered a first step toward defining general
microbial dysbiosis. The software framework, microbiome profiles, and metadata for thousands of samples are publicly available at http://segatalab.cibio.unitn.it/tools/metaml.

Author Summary
The human microbiome–the entire set of microbial organisms associated with the human
host–interacts closely with host immune and metabolic functions and is crucial for human
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health. Significant advances in the characterization of the microbiome associated with
healthy and diseased individuals have been obtained through next-generation DNA
sequencing technologies, which permit accurate estimation of microbial communities
directly from uncultured human-associated samples (e.g., stool). In particular, shotgun
metagenomics provide data at unprecedented species- and strain- levels of resolution. Several large-scale metagenomic disease-associated datasets are also becoming available, and
disease-predictive models built on metagenomic signatures have been proposed. However,
the generalization of resulting prediction models on different cohorts and diseases has not
been validated. In this paper, we comprehensively assess approaches to metagenomicsbased prediction tasks and for quantitative assessment of microbiome-phenotype associations. We consider 2424 samples from eight studies and six different diseases to assess the
independent prediction accuracy of models built on shotgun metagenomic data and to
compare strategies for practical use of the microbiome as a prediction tool.

Introduction
The human microbiome constitutes the whole set of microbial organisms associated with the
human host. It has been shown to be crucial for human health and for the development and
maintenance of the immune system and for several metabolic activities [1–3]. Significant effort
has been devoted to its characterization in healthy individuals and subjects with a variety of
diseases such as inflammatory bowel diseases [4,5], obesity [6,7], and type-2 diabetes [8]. Consequently, the potential use of the microbiome as a diagnostic tool is a promising line of investigation [9]. In addition, even when the findings are not immediately relevant for the clinical
setting, identifying associations between the microbiome and specific diseases is essential for
follow-up mechanistic studies.
Next-generation DNA sequencing technologies permit comprehensive profiling of the
microbial communities from human-associated samples, and have now been sufficiently
widely employed to enable meta-analysis for discovering patterns common to independent
studies. Meta-analysis has been broadly adopted in other genomics applications, such as for
analysis of microarray or RNA-seq data, where multiple studies have been performed for a similar purpose including identifying gene expression signatures of specific human cancers. The
general objectives of meta-analysis include proposing new classifiers [10], comparing different
classification methods [11], finding a common transcriptional profile [12], and evaluating generalization of prediction models across different studies [13]. In genomics, rigorous meta-analyses are crucial both to validate the findings of each single study, and for providing robust
models for clinical purposes.
The most common and cost-effective approach for microbiome characterization to date targets the 16S rRNA gene as taxonomic marker [14]. Meta-analyses and independent validation
of such experimental approach have identified differences in microbiome composition or function by body site, age, and disease state [15–17], and have been conducted to determine the
most effective techniques for disease classification [18]. More recently, shotgun metagenomics
[19] provided expanded resolution to the level of microbial species [20–22] and strain [23], to
the fungal and viral kingdoms [24], and to the level of individual genes across the metagenome
[25,26]. The decreasing cost of shotgun metagenomics is rapidly increasing the number of
available human disease-associated datasets; however, the generalization of resulting prediction
models is still unclear.
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Improved resolution and lower variability of shotgun metagenomics hold the promise to
provide improved generalization of microbial signatures over 16S rRNA sequencing [27].
Meta-analyses on specific host characteristics have been performed (e.g., with respect to host
age [28]). The importance of cross-cohort consistency and validation of predictions has also
been recognized, with some works assessing the structure of the microbiome in European
cohorts [29] and combined European-American cohorts [21, 30]. Some studies focusing on the
link between host conditions and microbiome further provided a validation step with respect
to other single investigations [31, 32]. Although these works provided a first assessment on the
transferability of condition-associated microbiome features across cohorts, no systematic
assessments have been performed on clinical outcomes using the full archive of shotgun metagenomic data now publicly available, and no convenient software frameworks for doing so are
available in the community.
In this study we uniformly process 2424 shotgun metagenomic samples from eight studies
to assess the independent prediction accuracy of models built on metagenomic data and to
compare strategies for practical use of the microbiome as a prediction tool. The software framework and the microbiome profiles for thousands of samples are made publicly available.

Results and Discussion
We evaluated alternative approaches to metagenomics-based prediction tasks, and assessed the
strength of microbiome-phenotype associations using publicly available raw sequence data.
For this purpose, we developed a machine-learning software framework which uses as features
quantitative microbiome profiles, including species-level relative abundances and presence of
species- and strain-specific markers (see Methods). Our multi-level validation strategy includes
the assessment of microbiome models on single cohorts, across stages of the same study, across
different studies, and across target outcomes and conditions (Fig 1). The software and validation framework is publicly available at http://segatalab.cibio.unitn.it/tools/metaml and was
applied on a total of 2424 publicly available metagenomic samples from eight large-scale studies (see Table 1 and Methods). All samples were processed with MetaPhlAn2 [21] for quantitative species- and subspecies-level taxonomic profiling after standard sequencing data preprocessing (see Methods).

Cross-validation studies revealed good capabilities for disease
prediction
We first assessed the prediction power of metagenomic data in linking the gut microbiome
with disease states. For such purpose, we considered six available disease-associated metagenomic datasets spanning five diseases: liver cirrhosis [33], colorectal cancer [34], inflammatory
bowel diseases (IBD) [35], obesity [31], and type 2 diabetes (two distinct studies—[37] and
[32]). Each dataset was analyzed independently using cross-validation (denoted as CV in Fig
1), which repeatedly uses part of the samples with associated known phenotype for learning
the statistical model, and the remainder for validating the predictions (see Methods). The support vector machines (SVM) [38] and random forest (RF) [39] classifiers were used for this
evaluation as they are state-of-the-art approaches and are appropriate for this type of data [18].
We also evaluated Lasso [40] and elastic net (ENet) [41] regularized multiple logistic regression. Neural networks [42] and Bayesian logistic regression [43] represent other possible alternatives not evaluated here.
Prediction performance was evaluated by the area under the curve (AUC) metric, which
summarizes true positive and false positive rates and is robust to unequal proportions of each
outcome. Using MetaPhlAn2 species abundance [21] as input data produced high accuracy for
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Fig 1. Validation strategies implemented in the developed framework. (a) Main strategies include cross-validation on single studies and crossvalidation across multiple studies. (b) Additional strategies when multiple stages are available from the same study.
doi:10.1371/journal.pcbi.1004977.g001

disease classification (Fig 2), although prediction performance varied considerably between
datasets. The most predictable disease state appears to be liver cirrhosis (AUC = 0.945, 95% CI:
0.909–0.981 for the best classifier), followed by colorectal cancer (AUC = 0.873, 95% CI: 0.802–
0.944), and IBD (AUC = 0.890, 95% CI: 0.812–0.968). For IBD we considered Crohn and ulcerative colitis patients together due to the low number of cases in the datasets compared to controls (as general rule at least ten samples per class are required for reliable prediction models).
Stronger signatures might be found when considering the two conditions separately with adequate sample size, as it has been observed that some bacterial features are specific to Crohn
Table 1. Summary of the datasets considered in the experiments.
Dataset
name

Body site

Disease

#stages #case samples #control samples Average reads per sample (std) Reference

Cirrhosis

Gut

Liver Cirrhosis

2

118

114

51.6M (30.9M)

[33]

Colorectal

Gut

Colorectal Cancer

1

48

73

60.0M (25.5M)

[34]

HMP

Several

None

1

-

981

61.1M (51.2M)

[1]

IBD

Gut

Inﬂammatory Bowel
Diseases

1

25

85

45.2M (18.4M)

[35]

Obesity

Gut

Obesity

1

164

89

68.2M (23.2M)

[31]

Skin

Skin

None

1

-

287

24.7M (38.1M)

[36]

T2D

Gut

Type 2 diabetes

2

170

174

40.2M (11.8M)

[37]

WT2D

Gut

Type 2 diabetes

1

53

43

31.0M (17.6M)

[32]

doi:10.1371/journal.pcbi.1004977.t001
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Fig 2. Cross-validation analysis for disease discrimination on six different datasets. Species abundance was used as microbiome feature. (a)
Prediction performance metrics for different diseases versus healthy controls. The margin of errors are reported in parenthesis. In bold we report the best
value for each dataset. (b) Average ROC curves (over folds) with confidence intervals for random forests (RF) and support vector machines (SVM).
doi:10.1371/journal.pcbi.1004977.g002

disease only [16]. Confounding factors such as active treatment could of course lead to overestimated prediction capabilities [44, 45], but we adopted here the same contrasting approach
used in the original works.
For the other diseases we achieved lower discrimination capabilities, suggesting less dramatic
microbial shifts in the patients. For type 2 diabetes, although the two considered datasets have
independently sampled and geographically distinct cohorts, we obtained very similar AUC values
for both (0.744, 95% CI: 0.688–0.800 and 0.762, 95% CI: 0.651–0.873 for T2D and WT2D,
respectively). Prediction of obesity generated the lowest AUC (0.655, 95% CI: 0.576–0.734).
Despite a wide range of classification performances, all investigated datasets showed a substantial
level of association between disease and the microbiome (Fig 2), with AUC values significantly
higher than those obtained by the same classifier applied to the same data with shuffled class
labels (p-values ranging from 9.9 × 10−3 for obesity to 5.6 × 10−7 for cirrhosis, S1 Table).
Comparing the accuracy of SVM and RF classifiers, RFs exhibited in all cases similar or better results than SVM. In particular, accuracies differed substantially for three datasets: AUC
increased from 0.809 to 0.873 for colorectal, from 0.663 to 0.744 for T2D (difference also supported by statistical significance, p-value 0.011, see S1 Fig), and from 0.664 to 0.762 for WT2D.
In two cases, slight improvements were verified: AUC increased from 0.922 to 0.945 for cirrhosis and from 0.862 to 0.890 for IBD. Methodologically, our results thus suggested the use of
RFs for disease prediction from species abundances.

Feature selection and strain-specific markers improve prediction
accuracy
We then investigated how feature selection, i.e., the procedure of selecting a reduced subset of
relevant discriminative features, impacts the prediction accuracy. To this end, we used the RF
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Fig 3. Prediction performances (assessed using AUC) for disease discrimination in different cross-validation
studies. Species abundance and marker presence are the microbiome features used by the classifiers. The best value for
each dataset and feature type (i.e., species abundance or marker presence) are in bold, and the overall best values for each
dataset are circled. RF and SVM are applied on the entire set of features whereas RF-FS:Emb incorporates a feature
selection step (see Methods). Margins of error are reported in parenthesis.
doi:10.1371/journal.pcbi.1004977.g003

classifier that implicitly embeds a feature selection step during the model generation phase (see
Methods). Feature selection produced a slight improvement of the AUC in all the cases when
the model was generated on a reduced set of species (Fig 3). The advantage of this procedure is
twofold. In addition to the increased accuracy, it enables biomarker discovery by detecting the
(few) species that are most useful to discriminate between “healthy” and “diseased” subjects.
These most discriminative species may be prioritized when performing follow-up and validation analyses, and the reduced complexity of the model potentially enables additional evaluations on low-throughput assays. However, the best accuracies were obtained with still relatively
high numbers of species, i.e., more than 60 (S2 Fig). This confirms the complexity of microbial
ecosystems where the combination of few species is probably not sufficient to characterize the
microbiome associated with complex diseases.
We then investigated the use of strain-specific markers, as opposed to species-level taxonomic abundance, by applying the same classification and cross-validation methods to strainspecific microbial features generated by MetaPhlAn2. Given their strain-specificity, adopting
markers as features let us also test the hypothesis that complex diseases are associated with the

PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004977 July 11, 2016

6 / 26

Machine Learning Meta-analysis of Large Metagenomic Datasets: Tools and Biological Insights

presence of specific strains or subspecies rather than only species-level abundances. Consistent
with this hypothesis, better predictions were obtained from markers (Fig 2) than species abundance, with differences that were statistically significant for one dataset (S1 Fig). This was
obtained using SVM with linear kernel, which in this context is more practical to use than RF
and SVM with more complex kernels due to the very high dimensionality (~100K features) of
the data. Focusing on SVM, markers gave statistically significant improvements with respect to
species abundances in half of the datasets (S1 Fig). Moreover, RF in combination with feature
selection (RF-FS:Emb) achieved satisfactory classification results, i.e., average accuracies were
usually worse than SVM but with no statistically significant difference (S1 Fig) even using a
very limited portion (<0.2%, S2 Fig) of the investigated markers. The biomarker discovery
step here is of particular interest because it permits identification of a limited set of strain-specific markers potentially directly involved in the association with disease.
We also considered alternative approaches to feature selection based on Lasso and ENet
(see Methods). Applying Lasso or ENet as pure classifiers, which implicitly incorporates the
feature selection and classification steps, did not give satisfactory results, with AUC worse than
RF or SVM for both species abundance and marker features (S3 Fig). Better accuracies were
obtained by using them for feature selection only, followed by RF or SVM classification. However, both Lasso and ENet feature selection in general worsened the performance of RF and
SVM without prior feature selection. Finally, ENet worked better than Lasso, although it was
associated with more time-consuming tuning of its free parameters on a two-dimensional grid.

Detection of the disease-associated microbial features
Feature selection can also be used for biomarker discovery, and several tools have been developed specifically for this task in metagenomics [46–48]. The approach proposed here (RF with
embedded feature selection) focuses on the set of features with the most discriminating power
rather than on strictly statistical assessments [46] or statistical assessment coupled with effect
size [47]. The implemented tool automatically plots the most relevant species (or markers)
with the importance factor (see Methods) along with the average relative abundance (or average presence) associated with the different considered classes. We observed a reasonable level
of overlap between the detected species and markers, as the most discriminative markers
tended to represent strains of the most discriminative species. Interestingly, for all the considered datasets (Fig 4 and S4 Fig) the importance factor attributed to each species (or marker)
was not well correlated with its average relative abundance (or presence) in the samples (maximum correlation of 0.49 for the T2D dataset, S5 Fig). In several cases, we detected relevant species with partial prevalence but highly discriminative potential between “healthy” and
“diseased” subjects. For example, Peptostreptococcus stomatis resulted the most discriminative
species in the colorectal dataset with an average relative abundance in the samples less than
0.15%.
In the cirrhosis dataset, the most relevant taxonomic abundances were enriched in diseased
patients. The top features were especially related to the Veillonella (Veillonella spp., Veillonella
dispar, Veillonella parvula, and Veillonella atypica) and Streptococcus genera (Streptococcus
anginosus and Streptococcus parasanguinis) in addition to Haemophilus parainfluenzae, which
is consistent with findings of the original study [33]. Species belonging to Veillonella and Streptococcus are typical colonizers of the oral cavity, but they are often overgrown in the small
intestine in patients affected by liver cirrhosis, thus suggesting the invasion of the gut from the
mouth in these patients [33]. Moreover, species such as Veillonella spp., V. dispar, V. atypica,
and S. anginosus were already associated with opportunistic infections [33]. Also the H. parainfluenzae pathogen may arrive to the gut from the oral cavity [33]. In the colorectal dataset we
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Fig 4. Most important discriminating species (left) and markers (right) identified by RF for disease discrimination in the (a) cirrhosis and (b)
colorectal cancer cross-validation studies. In the left panels, for each species reported on the vertical axis, the top bar (in blue) corresponds to the
feature relative importance (with standard deviation reported with error bars) and the two bottom bars refer to the average relative abundance for healthy
(in green) and diseased (in red) samples. In the right panels, for each marker the top bar is coloured according to the corresponding species and the two
bottom bars refer to the average marker presence.
doi:10.1371/journal.pcbi.1004977.g004
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identified five major species: P. stomatis, Fusobacterium nucleatum (both enriched in diseased
patients) and Streptococcus salivarius (depleted in diseased subjects) as found in the original
study [34], in addition to Parvimonas spp. and Parvimonas micra.
We then compared the discriminative species across datasets through hierarchical clustering
(S6 Fig). We found some species that were distinctive of one disease only as it is the case for P.
stomatis, P. micra and Gemella morbillorum in colorectal cancer, multiple Veillonella species in
cirrhosis, and, partially, Bifidobacterium bifidum and Lachnospiraceae in IBD. Interestingly, F.
nucleatum was highly discriminant both in colorectal cancer and cirrhosis, suggesting the presence of a similar dysbiosis niche for this organism. Overall, the discriminative species for the
two diabetes datasets and the obesity dataset had lower weights, consistent with the lower classification performances achieved with them. Moreover, the pattern of discriminative species
for these two datasets clustered together (S6 Fig), suggesting similar dysbiotic configurations
of the gut microbiome for obesity and type-2 diabetes. Some species were also found in the set
of top discriminative features for all the studies, in particular S. salivarius, S. anginosus, V. parvula, Roseburia intestinalis, and Coprococcus comes. These species might thus be biomarkers of
general dysbiosis or ecological community stress in non-healthy states, and should be recognized as such in future disease-microbiome association studies.

Extension to non-disease classification problems
We extended the cross-validation analysis by evaluating the predictability for non-disease based
classification problems. Gender discrimination (S7 Fig, part a) exhibited in general low classification accuracy with an AUC close or less than 0.6 for most of the considered datasets. However,
statistically significant discrimination was verified in some cases (AUC equal to 0.662 and 0.796
for skin and IBD dataset, respectively, both p < 0.05 by permutation test with shuffled labels),
which may suggest some gender-dependent differences in the human microbiome as highlighted
by recent studies [49]. High classification accuracy in body site prediction in the Human Microbiome Project (HMP) dataset (AUC = 0.96), is consistent with previously reported large differences in the microbiome composition among different body areas [1], and provided validation of
the proposed tool for multi-class classification problems (S8 Fig). The confusion matrix revealed
moderate misclassification between nasal and skin body sites, which may be due to nasal samples
being taken from the anterior nares (external part of the nostrils), and thus having relatively similar biochemical characteristics compared to skin samples from the retroauricular crease.

Metagenomic disease-predictive models show strong cross-stage
generalization
The cross-validation studies discussed in previous sections permitted evaluation of the predictability of different disease states from the human microbiome. However, they are not necessarily a good proxy to evaluate the generalization of the prediction model to independent
validation samples, a scenario more relevant to a clinical setting but that has been scarcely
investigated. Specifically, how do prediction models perform when applied to samples generated in an independent clinical and laboratory study? We address this question for several
problems of increasing complexity (denoted as CStaV in Fig 1).
We first considered the cirrhosis dataset, in which the samples were acquired in two distinct
stages named “discovery” and “validation” (Fig 5). The generalization of the model was evaluated by (i) generating the model on the samples of the training (TR) stage and (ii) applying it
on the test (TS) stage. For comparison, we also report the cross-validation results obtained on
each specific stage. In general, we found that the model was transferred properly from one
stage to the other. In fact, RF applied on species abundance produced an AUC value on the
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discovery stage that was only slightly decreased from 0.936 (for cross-validation) to 0.919. For
the validation stage we actually obtained an increase from 0.958 (for cross-validation) to 0.972,
and the marker-based predictions achieved slightly better but overall consistent values (Fig 5).
Finally, we note that the AUC achieved on each specific stage were in line with the AUC exhibited by cross-validation using the entire set of samples (0.945).
A similar analysis was done on the T2D dataset, in which samples were collected in two different stages (stageI and stageII, Fig 6). We verified sufficient generalization of the model
across the two stages, although we observed a decrease in accuracy relative to cross-validation.
AUC for RF on species abundance decreased from a cross-validation value of 0.737 (0.735 for
marker presence) to 0.661 (0.639) for stageI, and from 0.743 (0.771) to 0.686 (0.672) for stageII.
In general, the results obtained on the cirrhosis and T2D datasets provide reasonably good generalization of the model when applied across disease stages, i.e., to independent samples/
batches from the same study. This implies that the samples, although associated with different
subjects and acquired at different time points, share common characteristics such the

Fig 5. Cross-stage analysis of disease discrimination in the cirrhosis dataset, which was generated in two independent
stages (discovery and validation). The “All” columns and rows show results when all samples are combined. When the training
(TR) and test (TS) stages coincide, the analysis was done in cross-validation (with the margin of error reported in parenthesis). In the
other cases, the model was generated on TR and then applied to TS. In bold we report the best value for each scenario and feature
type (i.e., species abundance or marker presence), and circled are the overall best value for each scenario.
doi:10.1371/journal.pcbi.1004977.g005
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Fig 6. AUC by cross-stage and cross-study analysis for T2D discrimination in the T2D and WT2D datasets. When the training (TR) and test
(TS) sets coincide, the analysis was done in cross-validation (with the margin of error reported in parenthesis). In the other cases, the model was
generated on TR and then applied to TS. In bold we report the best value for each setting and feature type (i.e., species abundance or marker
presence), and circled are the overall best value for each scenario.
doi:10.1371/journal.pcbi.1004977.g006
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population of study, sample collection approach, DNA extraction protocol, sequencing technology, and analysis strategy [19].

Cross-study generalization is improved by including healthy samples
from other cohorts
Cross-study validation (denoted as CSV in Fig 1) is a more difficult standard of validation than
cross-stage validation, in that training and validation are performed in completely independent
studies targeting the same disease. We focused on type-2 diabetes, for which two distinct datasets are available (i.e., T2D and WT2D). The two datasets presented very different population
characteristics as T2D targeted Chinese subjects while WT2D enrolled European women. Still,
we observed generalization from one study to the other, (Fig 6), although cohort effects clearly
affected the results. For validation on the T2D dataset, the AUC for RF on species abundance
decreased from a cross-validation value of 0.744 (0.747 for marker presence) to 0.569 (0.566)
when the model was constructed on the WT2D dataset. Similarly, for validation on the WT2D
dataset, AUC decreased from a cross-validation value of 0.762 (0.739) to 0.664 (0.622). Different
results were achieved by transferring the model to WT2D from the two different experimental
stages of the T2D dataset. We obtained an AUC of 0.585 (0.595) and 0.689 (0.637) by transferring
the model from T2D_stageI and T2D_stageII, respectively, indicating that T2D_stageII was
more similar than T2D_stageI to WT2D. This similarity was consistent with integrative correlation [50] between the feature relative importance scores obtained on the considered stage of T2D
and those on WT2D (S2 Table). The features of T2D_stageII were more correlated to WT2D
than were T2D_stageI features, in agreement with the prediction accuracies.
Cross-study validation of T2D classification was improved by adding gut microbiome samples from the healthy subjects of four other datasets, i.e., cirrhosis, colorectal, HMP, and IBD,
to the training data. While we included all the control groups as “healthy”, there is the potential
for health problems among some control subjects. However, it is standard practice in case-control studies to exclude known disease conditions from control groups, so we can assume that,
even in the worst case, just a few diseased patients may be included in the controls and these
may be mostly due to undiagnosed cases. In this setting we tested the generalization of the
model across cohorts (Fig 7A) by generating the models on all the available samples apart
those associated with the dataset considered for testing, a "leave-one-dataset-out" cross-study
validation [51] (denoted as lodoCSV in Fig 1). Interestingly, we obtained improved discrimination for T2D when control samples from multiple independent studies were added to training
sets, with a high cross-validation AUC score in predicting type-2 diabetes on the entire set of
samples (0.837/0.806 for species abundance and marker presence using RF, respectively). These
values were in fact higher than the AUC obtained by merging all the T2D and WT2D samples
into a single set and cross-validating them (0.743/0.736). This cross-validation accuracy was
reduced when we tested the generalization of the model to the two T2D datasets (from 0.743/
0.736 to 0.655/0.653 and 0.709/0.679 for T2D and WT2D, respectively), which confirmed a noncomplete generalization of the model across cohorts. Interestingly, such values obtained by
including healthy samples from other cohorts were again higher than for models constructed
only on the T2D or WT2D datasets (Fig 6). Thus, including healthy samples from independent
cohorts was effective at improving the detection of T2D status. Finally, we evaluated generalization on the healthy samples of the four other datasets (prediction assessed in terms of overall
accuracy–OA, right part of Fig 7A). In such cases we verified high accuracy (i.e., OA close to 1
for all the considered datasets), confirming correct prediction for most of the control samples.
Addition of independent healthy samples to training sets was also performed for gender prediction (S7 Fig, part b), also resulting in increased accuracy, although the discrimination capabilities
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Fig 7. Cross-study analysis in multiple gut datasets for (a) T2D discrimination and (b) disease discrimination (independently from the type of
disease). For (a), we included all the healthy (controls) and diabetes (cases) samples, whereas samples labelled as other diseases were not considered.
For (b), we instead included all the samples where samples with one of the considered diseases were put together in the same "diseases" class. The *
denotes cross-validation results (with the margin of error reported in parenthesis). In the other cases, the model was generated on all the datasets other
than the dataset considered for testing, a “leave-one-dataset-out” cross-study validation [51]. For the testing datasets with only healthy samples,
prediction accuracy was evaluated in terms of overall accuracy (OA). In bold we report the best value for each scenario and feature type (i.e., species
abundance or marker presence), and circled are the absolute best value for each scenario.
doi:10.1371/journal.pcbi.1004977.g007

remained generally low. Overall, these results strongly suggest that the inclusion of samples of
healthy individuals from unrelated cohorts is beneficial in disease-targeted investigations, especially when the prediction task has to be generalized to new cohorts.

Avoiding overfitting is crucial to generalization on different cohorts
We compared the cross-validation accuracies that we obtained (Fig 3) with results reported in
the original papers, when available. For cirrhosis, our best AUC value was 0.963, higher than
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the cross-validation result reported in [33] (AUC = 0.838). Slight improvements were also verified for colorectal cancer (AUC = 0.881 against the 0.84 reported in [34]). The best AUC for
discrimination of IBD patients in the IBD dataset was 0.914, while a similar analysis was not
performed in the original paper [35].
For the other datasets (i.e., obesity, T2D, and WT2D), the original works used a two-step
procedure that tends to overstate discrimination accuracy: i) first a statistical test was applied
on the entire set of samples to select the most discriminative features, then ii) the model was
generated on this set of features and the prediction accuracies were estimated directly on the
training set or through a cross-validation approach. This approach overestimates accuracy
metrics such as AUC because supervised feature selection is applied on the same data used to
evaluate the model, a problem referred by the machine learning community as overfitting [52].
When we adopted the same overfitting-prone procedure, our cross-validation accuracy estimates (especially using marker features) were higher than the original ones for all datasets (S9
Fig), but as discussed these are overestimations of the actual discriminative power of the
models.
Conversely, the overfitting-prone method resulted in much worse performance when the
model was transferred to different cohorts. For example, the results reported in [32] showed an
AUC equal to 0.83 when cross-validating on WT2D, which decreased significantly to 0.66
when the model was transferred from the T2D dataset. For the same dataset, we estimated an
AUC of 0.785 (Fig 3) and 0.701 (Fig 6) by (non-overfitted) cross-validation and cross-study
validation, respectively. Non-overfitted models in general exhibit cross-validation accuracies
that are lower, but better represent the ultimate goal of generalization of the model to independent cohorts.
We stress that the use of a strict, complete cross-validation/cross-study validation approach
is necessary in metagenomics. For cross-validation this requires that for each fold, all training
steps (including feature selection, model selection, and model construction) are applied on a
set of samples that are not overlapping with the samples used for model evaluation/testing.
This, together with reducing confounding factors such as antibiotic usage, is necessary for nonoverfitted and non-overestimated assessment of the prediction capabilities of metagenomic
data.

Modelling the “healthy” microbiome: Cross-disease prediction
We finally tested the hypothesis that the distinction between the “healthy” and disease-associated gut microbiome can be generalized to diseases for which training information is not available. For this purpose, we considered all gut samples from the disease-associated datasets for a
total of 903 samples (Fig 7B). Here the class “diseased” included patients affected by the set of
disparate diseases discussed above. The cross-validation analysis on the entire set of samples
exhibited satisfactory results (AUC = 0.821 for the best model; most discriminative features are
reported in S10 Fig, part a, although in this scenario the model may in reality classify each
type of disease separately from the others. More interesting are the results of cross-study and
cross-disease prediction. In such cases the disease associated with the testing cohort was not
present in the datasets used to generate the model. Although the obtained AUC were lower
than the disease-specific cross-validation results reported previously in Fig 3, we still verified
in all cases a certain level of generalization of the model. In particular, the AUC varied between
0.628 (for T2D) and 0.872 (for cirrhosis). This represents an intriguing result that can be associated to the task of modelling the features of the “healthy” microbiome for use as a dysbiosis
prediction model for syndromes where few or no training samples are available. As expected,
several disease-specific species such as G. morbillorum, B. bifidum and P. micra were not
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among the most discriminative, the diseases with which they are correlated are not in the training set (S10 Fig, part b). Conversely, species discriminative for multiple diseases (S. salivarius,
S. anginosus, V. parvula, R. intestinalis, and C. comes) are even more relevant here, confirming
that these species are associated to a general non-healthy microbiome state rather than to specific host conditions (especially S. anginosus, which is the most relevant feature for four of the
five testing datasets). Overall, this suggests that the dysbiosis-associated microbiome is partially
distinct from the healthy microbiome regardless of the specific disease under investigation.
This also confirms that study-specific confounding factors [44, 45] are only partially affecting
the estimation of the classification performance. These species identified as associated to general microbiome dysbiosis should be considered in future microbiome studies as non-specific
responses to dysbiosis rather than as organisms directly involved in the pathogenesis of the disease under study.

Conclusion
We uniformly processed shotgun metagenomic microbiome data for 2424 samples from 8
studies of 6 disease types, and used cross-validation, cross-study validation, and cross-disease
validation to evaluate the accuracy of candidate methods of predictive modelling of disease
states. We make recommendations of best approaches and non-overfitted practices for using
the microbiome as a prediction tool and discuss species and strain-level biomarkers we identified for single and combined datasets. While in this manuscript we focused on taxonomic
information, metagenomic functional data such as gene or gene-family abundance data [53]
can be exploited in a similar way to conduct a more advanced function-based analysis. Future
work will be devoted to exploring more advanced machine learning strategies to further
improve classification performance.
In general, cross-validation revealed good prediction capabilities, however classification
results varied considerably between prediction tasks. In some cases, the ability to predict disease in undiagnosed cases may be overestimated due to the presence of confounding factors
such as active antibiotics treatment. The influence of confounding factors on human microbiome has been scarcely investigated in the literature [54, 55], but recent studies [44, 45] highlight this problem and question the study design of some works.
Cross-study validation involved evaluating the transferability of prediction models between
completely independent patient cohorts. We verified generalization across studies, although
transferred models were in some cases less accurate than models tested by within-study crossvalidation. Interestingly, the inclusion of healthy (control) samples from independent cohorts
in training sets was effective for improving the transferability of predictions. We emphasize
that considering cross-study performance, instead of the more traditional cross-validation
approach, is necessary to understanding prediction capabilities from metagenomic data [56].
Furthermore, avoiding overfitting is crucial for transferring models between different cohorts.
Finally, we obtained promising results in the ambitious task of modelling the features of the
“healthy” microbiome for use as a dysbiosis prediction model for syndromes where few or no
training samples are available. Importantly, this setting is not affected by confounding factors
on the target dataset since target samples are not used to build the model. The identified biomarkers for the “healthy” versus “dysbiosis”-associated microbiome are also very important for
future microbiome studies of new diseases, because if the same biomarkers are appearing as
discriminatory they should be regarded as general dysbiotic organisms rather than microbes
directly in involved in the disease under investigation.
Compared to the considerable amount of work done on learning methods for 16S rRNA
studies, our contribution emphasized two strengths unique to the shotgun metagenomic
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approach. First, we showed that improved performance can be achieved using strain-level
genomic features (i.e., markers) that are not available from 16S rRNA studies. This is also a
confirmation that many disease phenotypes are likely linked with microbial genes and factors
that are not “core” components of microbial species, but rather are encoded in variable genomic portions that are strain- or subspecies-specific. Second, despite the common potential
biases in DNA extraction, shotgun sequencing is considered more consistent across studies
than 16S rRNA sequencing for which different variable regions and primer choices are available [57–59], and thus quantitative microbial signature are inherently less difficult to transfer
across cohorts and populations. From a more technical viewpoint, learning analysis in shotgun
metagenomes presents distinct challenges due to the very high dimensionality of the dataset
when considering strain-level markers (~100K features), requiring different considerations in
machine learning than for 16S rRNA datasets. Altogether, we provide the first validated
toolbox for disease prediction across studies using shotgun metagenomics.
This study provides a publicly available software framework and uniformly processed
microbiome profiles for thousands of samples, to facilitate follow-up studies and evaluation of
new methods for classification of disease and other states using metagenomic data. This tool
allowed us to assess the predictive power of the microbiome features with respect to disease
states and transferability across independent datasets. On a final note, we notice that metaanalyses like the one we performed here were recently regarded as “research parasitism” [60],
because we analyse data produced by other laboratories. The analysis of cross-study predictions, and identification of a dysbiotic microbiome, would not be possible any other way. We
hope that not only will these results inform future clinical microbiome studies of disease, but
that they promote data transparency and re-use as key components of scientific progress.

Methods
The proposed tool
We developed a computational tool for metagenomics-based prediction tasks based on
machine learning classifiers (i.e., support vector machines (SVMs), random forests (RFs),
Lasso, and Elastic Net (ENet)). The tool uses as features quantitative microbiome profiles
including species-level relative abundances and presence of strain-specific markers. The framework is fully automatic, including model and feature selection, permitting a systematic and
non-overfitted analysis of large metagenomic datasets. Two main kinds of analysis are implemented, i.e., cross-validation (to evaluate the prediction strength of metagenomic data) and
cross-study (to evaluate the generalization of the model between different studies). Additionally, the most relevant features are detected for biomarker discovery tasks. Finally, a set of tools
is provided to evaluate classification performances in different ways including i) evaluation
metrics such as overall accuracy (OA), precision, recall, F1, and area under the curve (AUC);
ii) receiver operating characteristic (ROC) curve plots; iii) confusion matrices; iv) plots of the
most relevant features in addition to average relative abundances; and v) heatmap figures.
The MetAML (Metagenomic prediction Analysis based on Machine Learning) tool is opensource and available online at http://segatalab.cibio.unitn.it/tools/metaml. All the species-level
taxonomic profiling and marker presence and absence data generated by MetaPhlAn2 and
used in this paper are available at the same address.

The adopted machine learning tools
The developed tool incorporates four classification approaches (i.e. SVM, RF, Lasso, and ENet)
which have been extensively applied in many different fields including computational biology
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and genomics [18]. The classifiers were implemented using the scikit-learn python package
[61].
SVMs aim at finding the hyperplane that maximizes the margin between the samples in different classes [38], a strategy with many theoretical and practical advantages [62]. Although
they are intrinsically linear, they can be extended to the non-linear case by mapping data into a
higher dimensional feature space by means of a kernel function. In this work, a radial basis
function (RBF) kernel was considered for classifying species abundances, while a linear kernel
was adopted for markers due to the sparsity of marker-based profiling. In both cases, the best
regularization parameter C (both for linear and RBF kernel) and the width parameter γ (only
for RBF kernel) were chosen in {2−5, 2−3, . . ., 215} and {2−15, 2−13, . . ., 23}, respectively, using a
5-fold stratified cross-validation approach. In cross-validation, samples are first randomly subdivided into k subsets (folds) of equal size. In particular, we use here stratified cross-validation,
in which folds are made to preserve the percentage of samples of each class. A single subset is
then used for the testing the model, and the remaining k−1 subsets are used for training. The
whole process is repeated k times, with each of the k subsets used once as the testing set. Finally,
the results on the k testing folds are averaged to produce a single accuracy evaluation. The
parameters that maximize the accuracy (or another metric of choice) are finally chosen. SVMs
are binary classifiers and, in this work, extension to multi-class classification problems was
obtained through the one-against-one approach [63]. Moreover, class posterior probabilities of
each sample were estimated from the predicted labels in the binary case using the Platt formulation [64], which, in the multi-class case, was extended as per [65].
RFs are an ensemble learning method which constructs a large number of decision trees at
training time and outputs the class that is the mode of the classes of the individual trees [39].
The free parameters of such classifier were set in this work as follows: i) the number of trees
was equal to 500; ii) the number of features to consider when looking for the best split was
equal to the root of the number of original features; iii) the quality of a split was measured
using the gini impurity criterion. Although a better estimation of such parameters may be
obtained through cross-validation, no significant variations were verified by empirical evaluation. We note that RFs can intrinsically deal with binary and multi-class classification problems
and give estimation of class probabilities. Moreover, they implicitly provides a list of the features sorted in terms of relative importance. Feature importance was computed in our case
using the strategy usually referred to as “gini importance” or “mean decrease impurity” [66].
These importance values were exploited to perform an embedded feature selection strategy
(denoted as RF-FS:Emb) implemented as follows: i) RF was applied on the whole set of available features; ii) features were ranked in terms of importance; iii) RF was re-trained on the top
k-th features, by varying k in the set {5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175,
200}; iv) the number of features that maximized the accuracy was chosen as the optimal number; v) the final model was generated by training RF on this reduced set of features.
Lasso [40] and ENet [41] are generalized linear modelling approaches that incorporate feature selection and regularization to increase prediction accuracy from high-dimensional and
collinear predictors. Lasso is based on a multiple logistic regression trained with L1-norm
penalized likelihood, while both L1 and L2 norms are penalized in ENet. In this work, we
exploited them in two main ways: i) directly applying Lasso or Enet as pure classifiers by training a regression model on the binary classification problem; and ii) using Lasso or ENet for feature selection and then applying SVM or RF on the selected features. In both cases, best
regularization parameters were estimated using a 5-fold stratified cross-validation approach.
For Lasso this implied to chose the alpha parameter in {10−4, . . ., 10−0.5} with values evenly
spaced on a logarithmic scale. For ENet, along with alpha the L1_ratio parameter was chosen
in [0.1, 0.5, 0.7, 0.9, 0.95, 0.99, 1.0].
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Validation and evaluation strategies
Two main kinds of analysis were performed in this work, i.e., cross-validation and crossstages/studies. For cross-validation studies, prediction accuracies were assessed by 10-fold
cross validation, repeated and averaged on 20 independent runs. We underline that model
selection and feature selection are done using only the training set thus avoiding overfitting
problems. In the cross-stages/studies case, all the samples of the first stage/study are considered
for training and thus used to generate the classification model including the model selection
and feature selection steps. The generalization of the model is evaluated by applying it on the
samples of the independent stage/study. In all the cases, the results obtained on the original
classification problem were compared with those obtained by a random classifier (denoted in
the paper as SVM-Shuffled and RF-Shuffled). For such purpose, we applied the same setting
after shuffling randomly the labels of all the samples.
Several different metrics were taken into account to evaluate classification performances.
First, we considered the OA, which is the percentage of correctly predicted samples. From the
confusion matrix three main metrics were computed: i) the precision (i.e., the number of correct positive samples divided by the number of samples predicted as positive); ii) the recall (i.e.,
the number of correct positive samples divided by the total number of positive samples); iii)
the F1 score, which is the harmonic mean of precision and recall, i.e., F1 = 2 (precision recall)/
(precision+recall). These three metrics (which range in [0, 1], where 1 indicates the best case)
can be computed for each class separately. For brevity, we report in the paper only the average
values: after calculating the metrics for each class, their average values, weighted by the number
of samples per class, are computed. For binary classification problems, class posterior probabilities were used to plot the ROC curve, which represents the true positive rate (i.e., the recall)
against the false positive rate (i.e., the number of wrong positive samples divided by the total
number of non-positive samples). From the ROC curve, we computed the widely-used AUC
statistic, which can be interpreted as the probability that the classifier ranks a randomly chosen
positive sample higher than a randomly chosen negative one, assuming that positive ranks
higher than negative. The AUC ranges in [0.5, 1], where 0.5 corresponds to random change.
In the comparison among classifiers, prediction accuracy was assessed by 10-fold cross-validation, repeated and averaged on 20 independent runs. The same folds were used for all classifiers, i.e.
training and test sets were identical for each classifier. In this way, the difference in performance of
two classifiers could be calculated directly as the difference in AUCs (or any other metric) within
each test fold. Mean difference and standard error were calculated for each 10-fold CV, then averaged across the 20 repetitions for smoothing. 95% confidence intervals on the difference in AUC
performance of two classifiers were calculated using the t-distribution with df = 9, i.e.:
95% CI :
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where AUC1ij and AUC2ij are the AUC of two classiﬁers in fold i of repetition j, and σj is the standard deviation of the AUC1ij−AUC2ij across i = 1. . .10 folds in repetition j. Similarly, p-values were
obtained from the t-statistic obtained with mean difference and standard error smoothed over the
20 repetitions:
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using two-tailed t-test with df = 9, noting that the AUC differences were approximately normally
distributed.
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In terms of feature selection, we reported the list of the 25 most important features found by
RFs. For each feature, we considered also the relative importance score, which is a real number
in the range [0, 1] with features that sum to 1. Feature selection is done for each run independently, and we report the average results.

The considered large metagenomic datasets
We initially considered a total of 2571 publicly available metagenomic samples (from eight
main studies/datasets) that were reduced to 2424 after pre-processing and curation (see next
sections). These are all the human-associated shotgun metagenomic studies with more than 70
samples and read length bigger than 70nt available as of January 2015. Six studies were devoted
to the characterization of the human gut microbiome in presence of different diseases. Cirrhosis included 123 patients affected by liver cirrhosis and 114 healthy controls [33]. Colorectal
consisted of a total of 156 samples, 53 of which were affected by colorectal cancer [34]. IBD
represented the first available large metagenomic dataset and includes 124 individuals, 25 were
affected by inflammatory bowel disease (IBD) [35]. Obesity included 123 non-obese and 169
obese individuals [31]. Two distinct studies were instead related to the alteration of the microbiome in subjects with type 2 diabetes (T2D). In the T2D dataset, 170 Chinese T2D patients
and 174 non-diabetic controls were present [37]. The WT2D focused on European women and
included 53 T2D patients, 49 impaired glucose tolerance individuals and 43 normal glucose tolerance people [32]. Among these six datasets, two of them comprise two independent stages.
For cirrhosis, 181 and 56 samples were collected during the so defined discovery and validation
phases, respectively. Similarly, for T2D, 145 and 199 samples were acquired during the first
(stageI) and second (stageII) stages, respectively. Additionally, two studies focused on healthy
subjects and not strictly related to the gut microbiome were also taken into account. HMP
included samples collected from five major body sites (i.e., gastrointestinal tract, nasal cavity,
oral cavity, skin, and urogenital tract). A subset of these samples were described in [1]. Finally,
skin was composed by 291 samples acquired from several different skin sites [36].

Extraction of species abundance and marker presence profiles from
metagenomic samples
The entire analysis was done by taking into account two types of features: species-level relative
abundances and presence of strain-specific markers. These features were extracted from the
metagenomic samples using MetaPhlAn2 [21] with default parameters. Species abundances
are real numbers in the range [0, 1] that sum up to 1 within each sample, while markers assume
binary values. Species abundance and marker presence profiles are characterized by very different numbers of features: in the hundreds for species abundance, and hundreds of thousands
for markers (the exact numbers of features for each dataset are detailed in Fig 2). Before applying MetaPhlAn2 the samples were subject to standard pre-processing as described in the SOP
of the Human Microbiome Project [1] without however the step of human DNA removal as
these publicly available metagenomes were deposited free from human DNA contamination.
Additionally, we removed reads with length less than 90 nucleotides. For the IBD and obesity
datasets the minimum length was set to 70 and 75, respectively, as these cohorts were
sequenced with shorter read-lengths. Few samples did not pass the minimum length requirement and were thus discarded.

Experimental setting
The experimental evaluation can be summarized into five main steps: 1) cross-validation analysis was done on the six disease-association datasets for evaluating the capabilities of
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metagenomic data for disease classification; 2) cross-stage studies were performed on the cirrhosis and T2D datasets in order to test the generalization of the model on independent collection batches from the same study; 3) in terms of T2D, the analysis was extended by taking into
account also samples from completely distinct cohorts; 4) cross-studies were also done to
model the features of the “healthy” gut microbiome for use as a dysbiosis prediction model for
syndromes where few or no training samples are available; 5) cross-validation and cross-study
analysis were applied to deal with different classification problem such as gender and body site
discrimination. We note that all the investigated classification problems, excluding the body
site discrimination, represented binary classification problems. Moreover, most of the analysis
was done in terms of disease classification, in which the objective was to discriminate between
“healthy” and “diseased” subjects.
1. Cross-validation analysis (see “Cross-validation studies revealed good capabilities for disease prediction”, “Feature selection and strain-specific markers improve prediction accuracy” and "Detection of the disease-associated microbial features") was done on 6 datasets,
in which we adopted the same settings used in the original papers. For such reason, in some
cases some samples were removed from the analysis. For cirrhosis, all the 232 available samples (subdivided into “healthy” and “affected by liver cirrhosis” subjects) were taken into
account. For colorectal we removed the individuals affected by “large adenoma”, which
resulted in a total of 121 samples. “Cancer” patients were discriminated from “healthy” subjects, which included also persons affected by “small adenoma”. IBD was composed by a
total of 110 samples, in which the “diseased” class included IBD patients affected by both
“Crohn's disease” and “ulcerative colitis”. For obesity, we discriminated between “lean”
(BMI  25 kg m -2) and “obese” (BMI  30 kg m -2) subjects for a total of 253 samples. Individuals having an intermediate BMI (i.e., > 25 and < 30 kg m -2) were excluded. All the 344
samples of the T2D dataset were considered to discriminate between “healthy” individuals
and “T2D” patients. The same classification problem was investigated in WT2D, in which
96 samples were taken into account after excluding impaired glucose tolerance women.
2. Cross-stage analysis (see “Metagenomic disease-predictive models show strong cross-stage
generalization”) was applied to the cirrhosis and T2D datasets, in which the samples were
collected in two independent stages. For cirrhosis, the 232 samples were constituted by 178
samples of discovery and 54 samples of validation. Similarly, for T2D, stageI and stageII
included 145 and 199 samples, respectively.
3. Cross-study/cohort analysis was done by taking into account gut samples from multiple
datasets. In particular, we focused on the discrimination between “healthy” and “T2D” subjects (see “Cross-study generalization is improved by including healthy samples from other
cohorts”). For this purpose, in addition to the T2D and WT2D datasets, we considered also
the “healthy” samples from four other datasets, for which “diseased” samples were excluded
since not related to “T2D”: cirrhosis, colorectal, HMP and IBD for a total of 908 samples.
The entire analysis (apart for the two experiments denoted in the figure with the  ) was
done to evaluate the generalization of the model, therefore all the samples were used for
training apart the dataset considered for test. For comparison, we investigated also crossvalidation studies (denoted with the  ). In such case, we considered a single sample per subject in order to avoid overestimation of the accuracies (this issue was present in the HMP
dataset only). The sample was chosen randomly from the available samples for each iteration. So the cross-validation on the entire set of samples (denoted as All ) was done on a
total of 827 samples.
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4. Cross-study analysis was also applied to discriminate between “healthy” and “diseased” subjects (independently from the type of disease) in gut samples (see “Modelling the “healthy”
microbiome: cross-disease prediction”). We considered five different datasets (i.e., cirrhosis,
colorectal, IBD, T2D, and WT2D) for a total of 903 samples. Therefore the class “diseased”
included patients affected by liver cirrhosis, colorectal cancer, IBD and T2D. Also in this
case all the analysis was done to evaluate model generalization, apart the cross-validation
study on the entire set of samples (denoted as All ).
5. Finally, the developed tool was applied to non-disease-based classification problems (see
“Extension to non-disease classification problems” and “Cross-study generalization is
improved by including healthy samples from other cohorts”). First, we considered gender
classification, in which therefore “female” were discriminated from “male” subjects. In this
case, we took into account six datasets acquired from different body sites: four from gut (i.e.,
cirrhosis, colorectal, IBD, and T2D), one from skin (i.e., skin), and one from multiple sites
(i.e., HMP). First, we did cross-validation studies, in which each dataset was analyzed independently from the others. Also in this case we considered only one sample per subject in
order to avoid overestimation of the accuracies. For such reason, HMP and skin were
reduced to 131 and 17 samples, respectively. Then, we performed a cross-study analysis on
gut samples (thus the entire skin and part of the HMP datasets were excluded). In such case,
we considered first all the available samples (for a total of 1016 samples) and then only the
“healthy” samples (for a total of 642 samples). Then, the implemented tool was validated on
a multi-class classification problem, which was represented by body site discrimination in
the HMP dataset. The available samples were subdivided into five major body sites [1]: gastrointestinal tract, nasal cavity, oral cavity, skin, and urogenital tract. Cross-validation analysis was done by considering one sample per subject. Moreover, we considered also the case
in which more than one sample per subject, but each from a different body site, was taken
into account.

Code and data availability
The MetAML (Metagenomic prediction Analysis based on Machine Learning) software is
open-source, written in Python and available online at http://segatalab.cibio.unitn.it/tools/
metaml together with all the data used and discussed in this work.

Supporting Information
S1 Table. Statistical test against the null hypothesis of equal AUC for classification of true
and shuffled labels using RF and SVM. The table reports the p-value for cross-validation analysis for disease discrimination on six different datasets using species abundance as microbiome
features. Average values with margins of error for AUC are reported in Fig 1.
(PDF)
S2 Table. Cross-study analysis for T2D discrimination in the T2D and WT2D datasets
using RF on species abundances. The AUC is computed by training the model on one stage of
T2D and testing it on WT2D (same results in Fig 5). The IntCorr is the integrative correlation
[50] between the feature relative importance scores obtained on the considered stage of T2D
and those on WT2D.
(PDF)
S1 Fig. Statistical test to compare classification of true labels using RF and SVM. The table
reports the p-values for the null hypothesis of no difference in AUC by 10-fold cross-validation,
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assessed by paired t-test, for disease discrimination on six different datasets using species abundance and marker presence as microbiome features. Comparisons that are statistically different
(p-value < 0.05) are highlighted in red. Average values with margins of error for AUC are
reported in Fig 2.
(TIFF)
S2 Fig. Average number of features selected by the different methods for disease discrimination in different cross-validation studies. The corresponding prediction performances are
reported in Fig 3 and S3 Fig.
(TIF)
S3 Fig. Prediction performances (assessed using AUC) for disease discrimination in different cross-validation studies using Elastic Net (Enet) and Lasso. Species abundance and
marker presence were used as microbiome features. The best value for each dataset and feature
type (i.e., species abundance or marker presence) are in bold, and the overall best values for
each dataset are circled. Enet and Lasso denote their use as classifier applied on the entire set of
features; RF(or SVM)-FS:Enet(or Lasso) denotes RF (or SVM) used as classifier on the reduced
set of features given by Enet (or Lasso). The margins of error are reported in parenthesis.
(TIF)
S4 Fig. Most important discriminating species (left) and markers (right) identified by RF
for disease discrimination in (a) IBD, (b) obesity, (c) T2D and (d) WT2D cross-validation
studies. In the left panels, for each species reported on the vertical axis, the top bar (in blue)
corresponds to the feature relative importance (with standard deviation reported with error
bars) and the two bottom bars refer to the average relative abundance for healthy (in green)
and diseased (in red) samples. In the right panels, for each marker the top bar is coloured
according to the corresponding species and the two bottom bars refer to the average marker
presence.
(TIF)
S5 Fig. Correlation between feature relative importance determined by RF and species relative abundance in six different cross-validation studies for disease discrimination.
(TIF)
S6 Fig. Hierarchical clustering on the feature relative importance score determined by running RF on species abundances in six different cross-validation studies for disease discrimination. Features and data sets were clustered using correlation similarity.
(TIF)
S7 Fig. (a) Cross-validation and (b) cross-study analysis for gender discrimination in multiple datasets. In bold: the best value for each scenario and feature type (i.e., species abundance
or marker presence); Circled: the absolute best value for each scenario.
(TIF)
S8 Fig. Body site discrimination for the HMP dataset. (a) Cross-validation results by considering one sample per subject or more than one sample per subject but each from a different
body site. (b) Normalized confusion matrix when using RF on species abundance.
(TIF)
S9 Fig. The importance of cross-validation analysis. Prediction capabilities for disease discrimination in the (a) obesity, (b) T2D and (c) WT2D datasets are overestimated if the most
relevant features (i.e., species abundance or marker presence) are pre-selected. Cross-validation
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prevents this problem.
(TIF)
S10 Fig. Most relevant features to discriminate between “healthy” and “diseased” subjects
independently from the type of disease in multiple gut datasets. (a) Most relevant species
(left) and markers (right) identified by RF by cross-validating on the entire set of samples. In
the left panel, for each species reported on the vertical axis, the top bar (in blue) corresponds to
the feature relative importance (with standard deviation reported with error bars) and the two
bottom bars refer to the average relative abundance for healthy (in green) and diseased (in red)
samples. In the right panel, for each marker the top bar is coloured according to the corresponding species and the two bottom bars refer to the average marker presence. (b) Hierarchical clustering on the feature relative importance score determined by running RF on species
abundances in a "leave-one-dataset-out" cross-study validation [51]. For each case the model
was generated on all the datasets other than the dataset considered for testing. Features and
data sets were clustered using correlation similarity.
(TIF)
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